Cargando…

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

A double-institution phase II study was performed in patients with metastatic renal cell carcinoma treated subcutaneously (s.c.) with interleukin 2 (IL-2) and alpha-interferon (INF-alpha). Thirty-eight patients were treated over a course of 7 weeks. Initially (day 1 + 2) patients received s.c. IL-2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ravaud, A., Négrier, S., Cany, L., Merrouche, Y., Le Guillou, M., Blay, J. Y., Clavel, M., Gaston, R., Oskam, R., Philip, T.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1969444/ https://www.ncbi.nlm.nih.gov/pubmed/8198979

Ejemplares similares

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.
por: Négrier, S., et al.
Publicado: (1992)

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial
por: Ravaud, A, et al.
Publicado: (2003)

Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.
por: Bain, C., et al.
Publicado: (1997)

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.
por: Philip, T., et al.
Publicado: (1993)

Pretreatment serum CRP and response to interleukin 2.
por: Blay, J. Y., et al.
Publicado: (1994)

A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.
por: Hamblin, T. J., et al.
Publicado: (1993)

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study
por: Allen, M J, et al.
Publicado: (2000)

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1996)

Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
por: Biesma, B., et al.
Publicado: (1992)

Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1995)

Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study.
por: Facendola, G., et al.
Publicado: (1995)

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.
por: Pichert, G., et al.
Publicado: (1990)

Intraventricular recombinant alpha-interferon in subacute sclerosing panencephalitis
por: Cianchetti, C., et al.
Publicado: (1991)

Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice
por: Ravaud, A, et al.
Publicado: (1999)

Clinical Utility of Serum Interleukin-8 and Interferon-Alpha in Thyroid Diseases
por: Kobawala, Toral P., et al.
Publicado: (2011)

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
por: De Mulder, P. H., et al.
Publicado: (1995)

Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.
por: Ligo, M., et al.
Publicado: (1989)

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
por: Johnston, S. R., et al.
Publicado: (1998)

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
por: Ahmed, F. Y., et al.
Publicado: (1996)

Therapy with high dose recombinant alpha 2 interferon (IFN-alpha 2) produces a depression in natural killer cell cytotoxicity.
por: Tank, B., et al.
Publicado: (1984)

Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha.
por: Reid, I., et al.
Publicado: (1991)

Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma.
por: Hersey, P., et al.
Publicado: (1985)

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
Publicado: (1985)

Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials
por: Mahmoudpour, Seyed Hamidreza, et al.
Publicado: (2019)

A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma.
por: Ravaud, A., et al.
Publicado: (1995)

Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
por: Geertsen, P F, et al.
Publicado: (2004)

Identification of Interleukin1β as an Amplifier of Interferon alpha-induced Antiviral Responses
por: Robichon, Katharina, et al.
Publicado: (2020)

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
por: Hoffmann, R., et al.
Publicado: (1998)

Recombinant Interferon Alpha-2b as Primary Treatment for Ocular Surface Squamous Neoplasia
por: Ghaffari, Reza, et al.
Publicado: (2021)

Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells
Publicado: (1989)

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.
por: Jayson, G. C., et al.
Publicado: (1998)

Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
por: Fiorentino, B., et al.
Publicado: (1992)

Effect of recombinant human interferon-alpha in vitro and in vivo on mitogen-induced lymphocyte blastogenesis in cats()
por: Weiss, R.C., et al.
Publicado: (1990)

Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines.
por: Banks, R. E., et al.
Publicado: (1997)

Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.
por: Lai, C. L., et al.
Publicado: (1989)

Activity of interferon alpha, interleukin 6 and insulin in the regulation of differentiation in A549 alveolar carcinoma cells.
por: McCormick, C., et al.
Publicado: (1995)

Acute and Sub-chronic Toxicity Study of Recombinant Bovine Interferon Alpha in Rodents
por: Yu, Hai-Yang, et al.
Publicado: (2021)

CD73-Dependent Regulation of Interferon AlphaA and Interleukin-10 in the Inflamed Mucosa
por: Sotnikov, Ilya, et al.
Publicado: (2010)

Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma
por: Furuya, Nobutaka, et al.
Publicado: (2011)

Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_81aeh1qkhslrth3kf97ksni1o8